Bempegaldesleukin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Bempegaldesleukin
Accession Number
DB15140
Type
Biotech
Groups
Investigational
Description

Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).

Synonyms
Not Available
External IDs
NKTR-214
Categories
UNII
BNO1JG5MZC
CAS number
1939126-74-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCancer, Advanced1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Neoplasms Metastasis / Urinary Bladder Neoplasms1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
1WithdrawnTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2RecruitingTreatmentCancer of the Ovary / Colorectal Cancers / Head and Neck Squamous Cell Carcinoma (HNSCC) / Melanoma / Neuroendocrine Carcinoma of the Skin / Renal Cell Adenocarcinoma / Sarcomas / Transitional Cell Carcinoma / Triple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentCarcinoma´╝îNon-Small-Cell Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma / Triple Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer (mCRPC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentNeoplasms Metastasis / Urinary Bladder Neoplasms1
2RecruitingTreatmentSarcomas1
3RecruitingTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:52 / Updated on September 02, 2019 20:28